the aid library

LIST OPTIONS

Filter

504

New generations free of HIV, syphilis, hepatitis B and Chagas disease in the Americas 2018

M. Alonso González; M. B. Mello; L. Sereno; et al. Pan American Health Organization; World Health Organization (Americas); Unicef (2019) C_WHO

- EMTCT Plus

Download (335)

View PDF (344)

ECOSOC Meeting “Addressing noncommunicable diseases and mental health: major challenges to sustainable development in the 21st century”

World Health Organization (2009) C_WHO

Discussion Paper "Mental health, poverty and development", July 2009

Download (199)

View PDF (192)

Air pollution and the noncommunicable disease prevention agenda: opportunities for public health and environmental science

Howse, E.; Crane, M.; Hanigan, I. et al. Environmental Research Letters (2021) CC

Air pollution is a major environmental risk factor and contributor to chronic, noncommunicable diseases (NCDs). However, most public health approaches to NCD prevention focus on behavioural and biomedical risk factors, rather than environmental risk factors such as air pollution. This article discus... more

Download (503)

View PDF (553)

CLIMATE CHANGE AND HEALTH IN MOZAMBIQUE: IMPACTS ON DIARRHEAL DISEASE AND MALARIA

USAID, ATLAS (2018) C1

This report outlines the results of a scientific study of the impacts of weather, climate variability, and climate change on health in Mozambique, with a focus on diarrheal disease and malaria.

Download (418)

View PDF (519)

Improving Prison Conditions by Strengthening the Monitoring of HIV, HCV, TB and Harm Reduction (Spain)

C. F. Bessa, G. N. lazo, G. V. Sauret Observatory of the Penal System and Human Rights (University of Barcelona); European Union (2015) C2

Mapping Report - Catalonia (Spain).

External Link

Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis

Singh-Phulgenda, S., Dahal, P., Ngu, R. et al. PLOS Neglected Tropical Diseases (2021) C1

Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ... more

Download (427)

View PDF (446)

From plan to impact - Progress towards targets of the Global action plan on dementia

Alzheimer's Disease International (2018) C2

Progress towards targets of the Global action plan on dementia

External Link

Diagnostics to support the eradication of yaws—Development of two target product profiles

Fongwen, N.; Handley, B.; Martin, D. et al. PLoS Neglected Tropical diseases (2022) CC

Yaws is targeted for eradication by 2030, using a strategy based on mass drug administration (MDA) with azithromycin. New diagnostics are needed to aid eradication. Serology is currently the mainstay for yaws diagnosis; however, inaccuracies associated with current serological tests makes it difficu... more

Download (238)

View PDF (243)

Patterns of funding allocation for tuberculosis control in fragile states

Warsame A.; Patel P.; Checchi F. International Journal of Tubercolosis and Lung Disease (2014) CC

The Creditor Reporting System was analysed for official development assistance funding disbursements towards TB control in 11 conflict-affectedstates, 17 non-conflict-affected fragile states and 38 comparable non-fragile states. The amounts of funding, funding relative to burden, funding relative to... more

External Link

Surveillance, prevention and control of leishmaniases in the European Union and its neighbouring countries

European Centre for disease prevention and control (ECDC) European Centre for disease prevention and control (ECDC) (2022) C_CDC

This technical report presents the epidemiology of human and animal leishmaniases in the EU and its neighbouring countries and concludes that the disease remains widespread and underreported in many countries of southern Europe, northern Africa, and the Middle East and that there is a need to improv... more

External Link

Tackling Antimicrobial Resistance

EuroHealth Observer European Observatory on Health Systems and Policies Eurostation (2020) C2

The focus of the current quarterly edition of Eurohealth (from the European Observatory on Health Systems and Policies) is Antimicrobial Resistance (AMR) and contains the following articles: • Strengthening implementation of AMR national action plans • Fostering clinical developmen... more

Download (645)

View PDF (1401)

Bangladesh Health System Review

Asia Pacific Observatory on Health Systems and Policies (2015) C1

Health Systems in Transition. Vol. 5 No.3 2015

Download (775)

View PDF (1261)

The Philippines Health System Review

Asia Pacific Observatory on Health Systems and Policies (2011) C_WHO

Download (268)

View PDF (367)

56th directing council - 70th session of the regional committee of WHO for the Americas

Pan American Health Organization; World Health Organization (Americas); Observatorio Regional de Recursos Humanos de Salud (2018) C_WHO

Washington, D.C., USA, 23-27 September 2018 Provisional Agenda Item 4.6 CD56/10, Rev. 1 31 August 2018 Original: Spanish

Download (1000)

View PDF (1750)

Malaria National Strategic Plan 2015-2020

National Malaria Control Programme (NMCP) Communicable Disease Control Division Directorate General of Health Services Ministry of Health & Family Welfare Bangladesh (2015) C1

Download (246)

View PDF (412)

Research and Development Priorities for COVID-19 in Africa

African Union; Africa CDC Centres for Disease Control and Prevention; World Health Organization WHO, et al. (2021) CC

February 2021. Improving our response to the ongoing COVID-19 pandemic in Africa requires regularly updated information, constant innovation, and considerable support towards research and development (R&D) for priorities that respond to the African realities. Shaping the research agenda and stimula... more

Download (446)

View PDF (675)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Taenia solium taeniosis/cysticercosis and the co-distribution with schistosomiasis in Africa

Braae, U.; Saarnak, C.; Mukaratirwa, S. et al. Parasites and Vectors (2015) CC

The major neglected tropical diseases, Taenia solium taeniosis/cysticercosis and schistosomiasis caused by Schistosoma mansoni or S. haematobium are presumed to be widely distributed in Africa. Taenia solium taeniosis/ cysticercosis has been reported as an emerging disease in different regions of Af... more

External Link

Eradication of Yaws: Historical Efforts and Achieving WHO's 2020 Target

K. Asedeu; C. Fitzpatrick, J.Jannin (2014)

PLOS Neglected Tropical Diseases September 2014 | Volume 8 | Issue 9 | e3016 DOI: 10.1371/journal.pntd.0003016

Download (352)

View PDF (543)

Deprived of the right to health. Sick and without medical care in Germany

Médecins du MondeDoctors of the World (2019) C1

Observatory report by Médecins du Monde/Doctors of the World Germany:“Deprived of the right to health. Sick and without medical care in Germany” gives a rare insight into the situation of those who have no or only limited access to the German health system.